vimarsana.com

Latest Breaking News On - Omni clinics - Page 1 : vimarsana.com

Novel once-a-week insulin: Is it better than daily injections?

Both insulins had similar efficacy in terms of dosage and weight change but there were more episodes of hypoglycemia (blood sugar levels lower than average) with the weekly dose, say experts.

China
Argentina
Mohali
Madhya-pradesh
India
Sandeeps-chhatwal
Surya-kant-mathur
Ashu-rastogi
Department-of-endocrinology
Institute-of-medical-education
Post-graduate-institute
Medical-education

Is once-weekly insulin shot better than daily mealtime injections in controlling blood sugar?

Both insulins had similar effectiveness in terms of dosage and weight change but there were more episodes of hypoglycemia (blood sugar levels lower than average) with the weekly dose. It is less likely to help people with Type 1 diabetes, those who have fluctuating levels of blood sugar, those who are ill, exercise vigorously or drink alcohol, say experts

India
Argentina
China
Mohali
Madhya-pradesh
United-states
Sandeeps-chhatwal
Surya-kant-mathur
Ashu-rastogi
Department-of-endocrinology
Institute-of-medical-education
Associate-professor

Docs give green light to diabetes drug helping in weight loss

The study, conducted by an international team of researchers, compared different doses of oral Semaglutide and found that the higher doses of 25 mg and 50 mg showed better results in reducing blood sugar levels and promoting weight loss compared to the lowest dose of 14 mg.

Mohali
Madhya-pradesh
India
Canada
Ashu-rastogi
Sandeeps-chhatwal
Department-of-endocrinology
Associate-professor
Internal-medicine-specialist
Omni-clinics
Fortis-hospital-mohali
Principal-investigator

A new weight loss find: 25 mg and 50 mg doses of Semaglutide can speed up weight loss, even among Indians

The superior glycemic control and weight loss compared with the current highest approved dose of 14 mg suggest that these higher doses may support individually tailored treatment goals, based not only on glucose-lowering but also body weight and cardiovascular risk reduction targets, says Dr KP Singh, Director of Endocrinology, Fortis Hospital, Mohali and the Principal Investigator of the Semaglutide trial in India

India
Mohali
Madhya-pradesh
Ashu-rastogi
Sandeeps-chhatwal
Department-of-endocrinology
Institute-of-medical-education
Fortis-hospital
Principal-investigator
Non-alcoholic-steatohepatitis
Associate-professor
Post-graduate-institute

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.